Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:KYMR NYSE:QGEN NASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$115.07$114.67$47.86▼$115.13$6.73B0.251.50 million shs14.67 million shsKYMRKymera Therapeutics$82.56-1.8%$83.94$28.06▼$103.00$6.79B2.06684,883 shs69,366 shsQGENQiagen$33.90+3.9%$40.29$32.60▼$57.81$6.98B0.642.29 million shs597,776 shsTRVITrevi Therapeutics$14.73-1.0%$12.82$5.38▼$16.12$2.09B1.071.49 million shs170,752 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%0.00%+0.21%+71.13%+99.19%KYMRKymera Therapeutics-2.30%+4.20%-1.12%+5.80%+179.68%QGENQiagen-1.27%-4.70%-20.22%-36.19%-25.97%TRVITrevi Therapeutics+2.62%+7.28%+12.81%+32.27%+125.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$115.07$114.67$47.86▼$115.13$6.73B0.251.50 million shs14.67 million shsKYMRKymera Therapeutics$82.56-1.8%$83.94$28.06▼$103.00$6.79B2.06684,883 shs69,366 shsQGENQiagen$33.90+3.9%$40.29$32.60▼$57.81$6.98B0.642.29 million shs597,776 shsTRVITrevi Therapeutics$14.73-1.0%$12.82$5.38▼$16.12$2.09B1.071.49 million shs170,752 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%0.00%+0.21%+71.13%+99.19%KYMRKymera Therapeutics-2.30%+4.20%-1.12%+5.80%+179.68%QGENQiagen-1.27%-4.70%-20.22%-36.19%-25.97%TRVITrevi Therapeutics+2.62%+7.28%+12.81%+32.27%+125.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 2.11Hold$111.87-2.78% DownsideKYMRKymera Therapeutics 2.96Moderate Buy$118.1043.05% UpsideQGENQiagen 2.50Moderate Buy$46.3836.80% UpsideTRVITrevi Therapeutics 3.00Buy$22.9055.47% UpsideCurrent Analyst Ratings BreakdownLatest TRVI, QGEN, KYMR, and ACLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026TRVITrevi Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$30.005/7/2026QGENQiagen TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$46.00 ➝ $40.005/6/2026TRVITrevi Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$20.005/6/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$106.005/6/2026TRVITrevi Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.005/6/2026TRVITrevi Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $23.004/30/2026KYMRKymera Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$119.004/30/2026QGENQiagen Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$43.004/29/2026QGENQiagen BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$44.00 ➝ $38.004/29/2026QGENQiagen Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral ➝ Outperform$53.00 ➝ $43.004/29/2026ACLXArcellx Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$22.29M301.95N/AN/A$6.96 per share16.53KYMRKymera Therapeutics$39.21M173.19N/AN/A$19.42 per share4.25QGENQiagen$2.09B3.34$3.50 per share9.70$17.89 per share1.90TRVITrevi TherapeuticsN/AN/AN/AN/A$1.43 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$228.93M-$4.07N/AN/AN/A-1,027.26%-55.42%-36.24%N/AKYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%N/AQGENQiagen$424.88M$1.9117.6912.603.2919.16%14.09%8.26%N/ATRVITrevi Therapeutics-$42.76M-$0.32N/AN/AN/AN/A-23.94%-22.76%N/ALatest TRVI, QGEN, KYMR, and ACLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 million5/5/2026Q1 2026TRVITrevi Therapeutics-$0.07-$0.09-$0.02-$0.09N/AN/A4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million3/17/2026Q4 2025TRVITrevi Therapeutics-$0.10-$0.06+$0.04-$0.06N/AN/A2/26/2026Q4 2025ACLXArcellx-$1.01-$1.01N/A-$1.01$13.40 million$1.65 million2/26/2026Q4 2025KYMRKymera Therapeutics-$0.77-$0.97-$0.20-$0.97$14.80 million$2.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/AQGENQiagen$0.260.77%N/A13.61%N/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.444.44KYMRKymera TherapeuticsN/A10.8110.81QGENQiagen0.443.903.31TRVITrevi TherapeuticsN/A19.6619.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%KYMRKymera TherapeuticsN/AQGENQiagen70.00%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%KYMRKymera Therapeutics15.98%QGENQiagen9.00%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8058.48 million53.60 millionOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionableQGENQiagen5,654206.07 million187.53 millionOptionableTRVITrevi Therapeutics20141.98 million116.00 millionOptionableTRVI, QGEN, KYMR, and ACLX HeadlinesRecent News About These CompaniesNan Fung Trinity HK Ltd. Boosts Holdings in Trevi Therapeutics, Inc. $TRVIMay 10 at 6:31 AM | marketbeat.comF m Investments LLC Buys New Position in Trevi Therapeutics, Inc. $TRVIMay 10 at 3:59 AM | marketbeat.comComerica Bank Has $1.04 Million Stake in Trevi Therapeutics, Inc. $TRVIMay 10 at 3:41 AM | marketbeat.comTrevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030May 9 at 5:04 AM | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street ZenMay 9 at 1:34 AM | marketbeat.comTrevi Therapeutics (TRVI) Gets a Buy from H.C. WainwrightMay 8, 2026 | theglobeandmail.comEquities Analysts Offer Predictions for TRVI Q2 EarningsMay 8, 2026 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2026 Earnings Call TranscriptMay 7, 2026 | insidermonkey.comResearch Analysts Set Expectations for TRVI FY2030 EarningsMay 7, 2026 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Receives "Buy" Rating from HC WainwrightMay 7, 2026 | americanbankingnews.comWhy Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030May 6, 2026 | finance.yahoo.comTrevi Therapeutics (NASDAQ:TRVI) Price Target Lowered to $23.00 at Needham & Company LLCMay 6, 2026 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)May 6, 2026 | marketbeat.comTrevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comTrevi Therapeutics Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPSMay 5, 2026 | marketbeat.comTrevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 5, 2026 | globenewswire.comPictet Asset Management Holding SA Purchases 1,520,754 Shares of Trevi Therapeutics, Inc. $TRVIMay 2, 2026 | marketbeat.comTrevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International ConferenceApril 30, 2026 | globenewswire.comTrevi Therapeutics (TRVI) Expected to Announce Quarterly Earnings on ThursdayApril 30, 2026 | marketbeat.comTrevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026April 28, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRVI, QGEN, KYMR, and ACLX Company DescriptionsArcellx NASDAQ:ACLXArcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Kymera Therapeutics NASDAQ:KYMR$82.56 -1.55 (-1.84%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Qiagen NYSE:QGEN$33.90 +1.27 (+3.90%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Trevi Therapeutics NASDAQ:TRVI$14.73 -0.15 (-1.01%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
